RV-8451 / Rivus Pharma - LARVOL DELTA

Rivus Pharmaceuticals to Present Preclinical Obesity Data for Muscle-Preserving, Oral GLP-1 RV-8451 at ObesityWeek (GlobeNewswire) - "'The data we are presenting at ObesityWeek build on our prior data and reinforce RV-8451's potential to deliver fat-specific weight loss while preserving muscle, which has not yet been achieved before with a GLP-1. We look forward to submitting our IND for RV-8451 in chronic weight management in the first quarter of 2027 to advance our highly-differentiated GLP-1 into the clinic'."

IND • Preclinical • Obesity

Rescuing Lean Mass: GLP-1R NPA RV-8451 Reverses Orforglipron-Induced Muscle Loss in DIO Mouse Model (OBESITY WEEK 2026) - No abstract available

Preclinical

Beyond Caloric Restriction: RV-8451 GLP-1R NPA Drives Fat-Specific Weight Loss in a DIO Mouse Model (OBESITY WEEK 2026) - No abstract available

Preclinical

RV-8451, a Pre-Clinical, Muscle-Preserving GLP-1R NPA, Outperforms Orforglipron in Obesity Models (OBESITY WEEK 2026) - No abstract available

Preclinical • Genetic Disorders • Obesity

Discovery of RV-8451, a Novel, Oral, Muscle-Preserving Small Molecule GLP-1 Receptor Agonist (ADA 2026) - "RV-8451 is the first muscle-preserving, non-peptide GLP1RA that delivers weight and fat mass loss while maintaining lean mass in preclinical obesity models. By reducing RER, RV-8451 may counteract metabolic adaptation and improve efficacy relative to current non-peptide GLP1RAs."

Metabolic Disorders • Obesity • ARRB1

Muscle-Preserving Weight Loss with RV-8451, a Novel, Oral Nonpeptide GLP-1 Receptor Agonist, in Diet-Induced Obese Nonhuman Primates (ADA 2026) - "RV-8451, a first-in-class, muscle-preserving non-peptide GLP1RA, produced robust WL in obese NHPs driven by selective fat loss, preservation of lean mass, and improvements in metabolic biomarkers, with no GI AEs observed. These results in NHPs, together with rodent data, support RV-8451 as the first muscle-preserving GLP1RA to address key limitations of current GLP1RA therapies. RV-8451 has advanced into IND-enabling studies to support a planned Phase 1 clinical trial."

Metabolic Disorders • Obesity

Rivus Pharmaceuticals Announces Preclinical Data for RV-8451, a Muscle-Preserving, Oral GLP-1, at ADA 2026 Scientific Sessions (GlobeNewswire) - "Results from a preclinical model of DIO NHPs treated with RV-8451 for 18 days following a 7-day vehicle acclimatation period showed: Energy Intake: 53% reduction in daily food intake (p<0.05 from baseline); Weight Loss: 9% reduction in body weight (p<0.05 from baseline); Fat Loss: Up to 20% reduction in fat mass (p<0.05 from baseline)....Results from a preclinical model of DIO NHPs treated with RV-8451 or orforglipron for 28 days showed: Weight Loss: Similar reductions in weight loss (7%); Fat Loss: Greater fat loss with RV-8451 compared to orforglipron (30% vs. 11% reduction, p<0.05)....IND‑enabling studies advancing, with IND submission for RV-8451 in obesity targeted for Q1 2027."

IND • Preclinical • Obesity